Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years

Open access
Andrews, Elizabeth B, Gilsenan, Alicia W, Midkiff, Kirk, Sherrill, Beth, Wu, Yun, Mann, Beth H, Masica, Daniel·2012·Journal of Bone and Mineral Research

Abstract

The Osteosarcoma Surveillance Study, an ongoing 15-year surveillance study initiated in 2003, is a postmarketing commitment to the United States (US) Food and Drug Administration to evaluate a potential association between teriparatide, rhPTH(1–34), a recombinant human parathyroid hormone analog (self-injectable medication to treat osteoporosis), and development of osteosarcoma in response to a finding from preclinical (animal) studies. Incident cases of primary osteosarcoma diagnosed in adults (aged ≥40 years) on or after January 1, 2003, are identified through population-based state, regional, and comprehensive cancer center registries in the US. Information on possible prior treatment with teriparatide, on demographics, and on risk factors is ascertained by patient or proxy telephone interview after patient consent. Between June 2004 and September 30, 2011, 1448 cases (diagnosed 2003 to 2009) were identified by participating cancer registries (estimated to be 62% of all adult cases in the US for that time period); 549 patients or proxies were interviewed. Interviewed patients were similar to noninterviewed patients with regard to mean age, sex, race, and geographical distribution and tumor type and site of tumor. Mean age of those interviewed was 61 years, 46% were female, 86% were white, and 77% were alive when the case was reported to the study investigators. Data collected in the study provide descriptive information on a large number of adults with osteosarcoma, an uncommon malignant bone tumor. After 7 years of the study, there were no osteosarcoma patients who had a prior history of teriparatide treatment. Thus, approximately halfway through this 15-year study, the study has not detected a pattern indicative of a causal association between teriparatide treatment and osteosarcoma in humans. © 2012 American Society for Bone and Mineral Research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jbmr.1768

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 272

Metadata

Authors
Andrews, E. B., Gilsenan, A. W., Midkiff, K., Sherrill, B., Wu, Y., Mann, B. H., & Masica, D.
Venue
Journal of Bone and Mineral Research
Published
2012-11-19
Volume
27
Issue
12
Pages
2429-2437
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W2075876977
Cited by
272
References
12
FWCI
16.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. https://app.cochat.ai/papers/10.1002/jbmr.1768
The paper
Andrews, E. B., Gilsenan, A. W., Midkiff, K., Sherrill, B., Wu, Y., Mann, B. H., & Masica, D. (2012). The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.1768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.